Comparable Cancer-Specific Mortality of Patients With Early Gastric Cancer Treated With Endoscopic Therapy vs Surgical Resection.


Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
11 2020
Historique:
received: 07 12 2019
revised: 27 04 2020
accepted: 29 04 2020
pubmed: 12 5 2020
medline: 19 8 2021
entrez: 12 5 2020
Statut: ppublish

Résumé

Endoscopic therapy is used commonly for superficial gastric cancer with very low risk of metastasis to the lymph nodes. However, limited population-based studies from the West have evaluated long-term outcomes of patients who received endoscopic therapy vs surgery. We used the Surveillance Epidemiology and End Results database to identify and compare features and outcomes of patients who underwent endoscopic therapy (n = 786) or surgery (n = 2577) for Tis or T1aN0M0 superficial gastric cancer, diagnosed from 1998 to 2014. Multivariate logistic regression was performed to identify factors associated with endoscopic therapy. Overall survival and gastric cancer-specific survival times were compared after we controlled for covariates. Use of endoscopic therapy increased from 15.1% of cases in 1998 to 2000 to 39.0% of cases in 2013 to 2014. Endoscopic therapy was used more frequently in patients who were older, female, or Caucasian, or with lesions that were located in the proximal stomach or were limited in depth (Tis vs T1a) and size, compared with surgery. The median follow-up time was 59 months (interquartile range, 31-102 mo). Percentages of 5-year overall and cancer-specific survival were 57% and 99% in the endoscopic therapy group and 76% and 95% in the surgery group. After we adjusted for clinical factors using a multivariate Cox proportional hazards model, we found no significant difference in gastric cancer-specific mortality between patients who received endoscopic therapy vs surgery (hazard ratio, 1.42; 95% CI, 0.91-2.23; P = .12). In an analysis of a large population database, we found an increased trend in endoscopic therapy for superficial gastric cancer compared with surgery from 1998 through 2014. Patients who received endoscopic therapy vs surgery had comparable long-term cancer-specific mortality.

Sections du résumé

BACKGROUND & AIMS
Endoscopic therapy is used commonly for superficial gastric cancer with very low risk of metastasis to the lymph nodes. However, limited population-based studies from the West have evaluated long-term outcomes of patients who received endoscopic therapy vs surgery.
METHODS
We used the Surveillance Epidemiology and End Results database to identify and compare features and outcomes of patients who underwent endoscopic therapy (n = 786) or surgery (n = 2577) for Tis or T1aN0M0 superficial gastric cancer, diagnosed from 1998 to 2014. Multivariate logistic regression was performed to identify factors associated with endoscopic therapy. Overall survival and gastric cancer-specific survival times were compared after we controlled for covariates.
RESULTS
Use of endoscopic therapy increased from 15.1% of cases in 1998 to 2000 to 39.0% of cases in 2013 to 2014. Endoscopic therapy was used more frequently in patients who were older, female, or Caucasian, or with lesions that were located in the proximal stomach or were limited in depth (Tis vs T1a) and size, compared with surgery. The median follow-up time was 59 months (interquartile range, 31-102 mo). Percentages of 5-year overall and cancer-specific survival were 57% and 99% in the endoscopic therapy group and 76% and 95% in the surgery group. After we adjusted for clinical factors using a multivariate Cox proportional hazards model, we found no significant difference in gastric cancer-specific mortality between patients who received endoscopic therapy vs surgery (hazard ratio, 1.42; 95% CI, 0.91-2.23; P = .12).
CONCLUSIONS
In an analysis of a large population database, we found an increased trend in endoscopic therapy for superficial gastric cancer compared with surgery from 1998 through 2014. Patients who received endoscopic therapy vs surgery had comparable long-term cancer-specific mortality.

Identifiants

pubmed: 32389885
pii: S1542-3565(20)30635-2
doi: 10.1016/j.cgh.2020.04.085
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2824-2832.e1

Informations de copyright

Copyright © 2020 AGA Institute. All rights reserved.

Auteurs

MirMilad Khoshknab Pourmousavi (MK)

Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland.

Rui Wang (R)

Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland; Department of Gastroenterology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.

Tossapol Kerdsirichairat (T)

Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland.

Ayesha Kamal (A)

Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland.

Venkata S Akshintala (VS)

Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland.

Gulara Hajiyeva (G)

Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland.

Chawin Lopimpisuth (C)

Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland.

Yuri Hanada (Y)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Vivek Kumbhari (V)

Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland.

Vikesh K Singh (VK)

Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland.

Mouen A Khashab (MA)

Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland.

Olaya Gutierrez Brewer (OG)

Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland.

Eun Ji Shin (EJ)

Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland.

Marcia I Canto (MI)

Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland.

Anne Marie Lennon (AM)

Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland.

Saowanee Ngamruengphong (S)

Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland. Electronic address: sngamru1@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH